Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Codexis, Inc. (CDXS : NSDQ)
 
 • Company Description   
Codexis is a leading protein engineering company that applies its proprietary CodeEvolver technology to develop proteins for a variety of applications, including as biocatalysts for the commercial manufacture of pharmaceuticals, fine chemicals and industrial enzymes, and enzymes as biotherapeutics and for use in molecular diagnostics. Codexis? proven technology enables improvements in protein performance, meeting customer needs for rapid, cost-effective and sustainable manufacturing in multiple commercial-scale implementations of biocatalytic processes.

Number of Employees: 261

 
 • Price / Volume Information   
Yesterday's Closing Price: $10.49 Daily Weekly Monthly
20 Day Moving Average: 1,048,133 shares
Shares Outstanding: 65.30 (millions)
Market Capitalization: $685.04 (millions)
Beta: 1.96
52 Week High: $42.01
52 Week Low: $9.47
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -26.13% -16.80%
12 Week -45.87% -40.50%
Year To Date -66.45% -59.09%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
200 PENOBSCOT DRIVE
-
REDWOOD CITY,CA 94063
USA
ph: 650-421-8100
fax: 650-421-8102
ir@codexis.com http://www.codexis.com
 
 • General Corporate Information   
Officers
John J. Nicols - President; Chief Executive Officer and Director
Byron L. Dorgan - Chairman of the Board of Directors
Ross Taylor - Senior Vice President and Chief Financial Officer
Jennifer Aaker - Director
Stephen Dilly - Director

Peer Information
Codexis, Inc. (CORR.)
Codexis, Inc. (RSPI)
Codexis, Inc. (CGXP)
Codexis, Inc. (BGEN)
Codexis, Inc. (GTBP)
Codexis, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 192005106
SIC: 2860
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 65.30
Most Recent Split Date: (:1)
Beta: 1.96
Market Capitalization: $685.04 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.11 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.44 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 4.32
Price/Cash Flow: -
Price / Sales: 5.61
EPS Growth
vs. Year Ago Period: 7.14%
vs. Previous Quarter: 18.75%
Sales Growth
vs. Year Ago Period: 95.98%
vs. Previous Quarter: 44.24%
ROE
03/31/22 - -12.56
12/31/21 - -12.90
09/30/21 - -9.02
ROA
03/31/22 - -8.93
12/31/21 - -9.47
09/30/21 - -6.87
Current Ratio
03/31/22 - 4.91
12/31/21 - 4.85
09/30/21 - 5.20
Quick Ratio
03/31/22 - 4.86
12/31/21 - 4.82
09/30/21 - 5.17
Operating Margin
03/31/22 - -16.85
12/31/21 - -20.31
09/30/21 - -14.82
Net Margin
03/31/22 - -16.85
12/31/21 - -20.31
09/30/21 - -14.82
Pre-Tax Margin
03/31/22 - -16.69
12/31/21 - -20.13
09/30/21 - -14.69
Book Value
03/31/22 - 2.43
12/31/21 - 2.53
09/30/21 - 2.62
Inventory Turnover
03/31/22 - 21.72
12/31/21 - 20.42
09/30/21 - 20.47
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©